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It has been 20 years since the original publication of the
MOPP program from the National Cancer Institute (Beth-
esda) (DeVita et al., 1970). During the succeeding years, we
have learned that the regimen can give consistent results
around the world and that survival is more determined by
clinical prognostic factors, such as stage, symptoms and per-
formance status (Longo et al., 1986). In addition, more
dynamic factors, such as the quantity of mustine delivered in
the first three cycles, and the rapidity of tumour regression,
predict better results. With these benefits came a variety of
toxicity problems related to this regimen. Mustine itself pro-
duced nausea/vomiting and phlebitis, which could result in
dose modification and delays in treatment because of poor
compliance by some patients. Severe myelosuppression may
occur with mustine which will result in similar irregularities
in the administration of MOPP. The Royal Marsden group
modified the MVPP regimen (mustine, vinblastine, procar-
bazine, prednisone) by the substitution of chlorambucil for
mustine (ChIVPP) with the first report in 1977 (McElwain et
al., 1977). The long-term follow-up of this and derivative
series confirms an effect which is indistinguishable from
MOPP or MVPP in comparable patients (Selby et al., 1990;
Druker et al., 1989; McKendrick et al., 1989). Given these
results now, clearly a randomised trial is not required. The
BNLI trial confirms the similarity of the chlorambucil-
containing regimen (LOPP) to MOPP. Further, the decreased
morbidity of ChlVPP was cofirmed. It is clear from this and
other trials that acute toxicity of MOPP or MVPP is not
necessary to achieve the benefits in advanced Hodgkin's
disease. The issue is not completely at rest, however, since the
publication of MOPP alternating with ABVD trials have
demonstrated a superiority to MOPP alone (Bonadonna et
al., 1986). In addition, the development of the hybrid regi-
men, MOPP-ABV, has again 'locked in' the use of mustine
since the initial very promising results captured the attention
of clinicians (Klimo et al., 1988). The Cancer and Leukemia
Group B (CALGB) trial comparing MOPP to ABVD alone
and both to the alternating MOPP-ABVD for 12 months
showed a superiority of ABVD alone over MOPP, and com-
parable results to the alternating regimen, MOPP-ABVD.
Differences in full-dose delivery were noted between MOPP
and ABVD since the latter did not seem to impair the bone
marrow function to the same degree as MOPP (Canellos et
al., 1988). The current Intergroup trial in North America is a
randomisation between ABVD alone and the MOPP-ABV
hybrid.
Clearly, dose rate is an important factor in the chemo-
therapy of drug responsive tumours. The ChlVPP or LOPP
program offer a high rate of dose intensity given the daily
administration of chlorambucil. Whether a dose schedule
calculated per m2 body mass and adjusted according to bone
marrow tolerance rather than a fixed maximum dose of
10 mg per day would have had better results is speculation.
With both LOPP and ChlVPP, the patient is not spared the
risk of treatment-induced leukaemia albeit a low risk. No
leukaemias have been noted with ABVD alone in the Milan
and CALGB trials (Valagussa et al., 1982). The current
directions include the exploration of dose intensification,
especially in poor prognosis patients. In the better prognosis
patients, clearly LOPP or ChlVPP could be substituted for
MOPP or MVPP.
Can all alkylating agent-containing regimens be replaced
by alternative programs which might reduce the likelihood of
sterility and leukaemogenesis without adding new chronic
toxicities? A number of trials have now suggested that
equivalent or superior results to MOPP can be achieved with
ABVD (Canellos et al., 1988; Santoro et al., 1987; Carde et
al., 1990). The next question - whether ABVD can be im-
proved - remains for future trials.
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